Although we cannot extrapolate our experimental in vivo results with Marimastat to human clinical trials directly, it is possible that Marimastat as well as other drugs with anti-TACE activity may have similar effects on hepatic steatosis. Here, ADAM17 is linked to fatty liver disease.